v3.26.1
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Segment Reporting

Note 10 – Segment Reporting

 

Due to the new digital asset treasury strategy, the Company now has two reportable segments: digital asset treasury and clinical stage bio-technology.

 

The Company’s Chief Executive Officer serves as the Chief Operating Decision Maker (“CODM”) and evaluates the financial performance of the business and makes resource allocation decisions on the basis of net income/(loss) before income taxes.

 

Summary segment financial performance measures evaluated by the CODM as of December 31, 2025 and 2024 and for the years then ended is as follows:

 

       
   Segment Assets at December 31, 
   2025   2024 
Digital asset treasury segment  $513,964,900   $- 
Clinical stage bio-technology segment   5,181,535    3,721,624 
Total assets  $519,146,435   $3,721,624 

 

Digital asset treasury segment

 

       
   For the years ended December 31, 
   2025   2024 
Loss from operations  $(2,765,292)  $- 
Other income (expense) (a)   24,117    - 
Unrealized loss on digital assets holdings   (22,010,362)   - 
Total loss before income taxes  $(24,751,537)  $- 

 

Clinical stage bio-technology segment

 

       
   For the years ended December 31, 
   2025   2024 
Loss from operations  $(17,340,774)  $(12,433,792)
Other income (expense) (a)   (11,052)   236,224 
Total loss before income taxes  $(17,351,826)  $(12,197,568)

 

(a)Other income (expense) consists of interest income and interest expense.

 

The following table is a reconciliation of segment total loss before income taxes to our consolidated total loss before income taxes.

 

         
   For the years ended December 31, 
   2025   2024 
Digital asset treasury segment total loss before income taxes  $(24,751,537)  $- 
Clinical stage bio-technology segment total loss before income taxes   (17,351,826)   (12,197,568)
Consolidated total loss before income taxes  $(42,103,363)  $(12,197,568)